ReviewFood science & nutrition2025
The Beneficial Effects of Resveratrol on Hepatocellular Carcinoma and Nonalcoholic Fatty Liver Disease: Modulation of Apoptosis, Autophagy, Inflammation, and Oxidative Stress.
Review in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress.Physiological research · 2026Article
- Review
- The Multidirectional Biological Activity of Resveratrol: Molecular Mechanisms, Systemic Effects and Therapeutic Potential-A Review.Nutrients · 2026Review
- Multi-Omics and Molecular Simulation Identify KIF11 as a Candidate Direct Target of Resveratrol in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- The Beneficial Effects of Resveratrol on Hepatocellular Carcinoma and Nonalcoholic Fatty Liver Disease: Modulation of Apoptosis, Autophagy, Inflammation, and Oxidative Stress.Food science & nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive liver fat accumulation that can progress to the more severe NASH. Impaired autophagy, the cellular process of recycling damaged organelles and proteins, has been observed in NAFLD. Interestingly, the compound resveratrol has been shown to induce autophagy in liver cells, potentially helping to alleviate NAFLD. Resveratrol can also trigger apoptosis, or programmed cell death, in hepatocellular carcinoma (HCC) cells, the most common form of liver cancer, by inhibiting key signaling pathways. This apoptosis-inducing effect highlights resveratrol's therapeutic potential for HCC. Additionally, the cytotoxicity of resveratrol in cancer cells suggests that it may selectively target and eliminate damaged or malignant cells, further contributing to its anticancer properties. Resveratrol activates the AMPK protein complex, which regulates energy balance and autophagy, suggesting it may help remove damaged cellular components in NAFLD. While preclinical studies are promising, further clinical research is still needed to evaluate the efficacy and safety of resveratrol for treating NAFLD and HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.